Deutsch English Français

Contact

EP1137762

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...

News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...

Extract from the Register of European Patents

EP About this file: EP1137762

EP1137762 - TREATMENT OF POMPE'S DISEASE [Right-click to bookmark this link]
Status	Patent revoked Status updated on 06.05.2016 Database last updated on 11.05.2024
Most recent event Tooltip	22.07.2016	Lapse of the patent in a contracting state New state(s): CH, LI	published on 24.08.2016 [2016/34]
Applicant(s)	For all designated states Genzyme Corporation 500 Kendall Street Cambridge, MA 02142 / US
	[2008/40]
Former [2003/47]	For all designated states GENZYME CORPORATION One Kendall Square Cambridge, Massachusetts 02139 / US
Former [2001/40]	For all designated states Pharming Intellectual Property BV Niels Bohrweg 11-13 2333 CA Leiden / NL
	For all designated states GENZYME CORPORATION One Kendall Square Cambridge, Massachusetts 02139 / US
Inventor(s)	01 / VAN BREE, Johannes, Brenardus, Mathias, Marie Dotterbloemstraat 27 NL-2153 ES Nieuw-Vennep / NL
	02 / VENNEKER, Edna, Henriette, Germaine Saturnushof 15 NL-3952 EE Maarn / NL
	03 / MEEKER, David, P. 39 Southfield Circle Concord, MA 01942 / US
	[2001/40]
Representative(s)	Adams, Harvey Vaughan John, et al Mathys & Squire LLP The Shard 32 London Bridge Street London SE1 9SG / GB
	[N/P]
Former [2006/11]	Adams, Harvey Vaughan John, et al Mathys & Squire, 120 Holborn London EC1N 2SQ / GB
Former [2005/33]	Bizley, Richard Edward, et al HLBBshaw Merlin House Falconry Court Baker's Lane Epping Essex CM16 5DQ / GB
Former [2001/40]	Williams, Richard Andrew Norman, et al Hepworth Lawrence Bryer & Bizley Merlin House Falconry Court Bakers Lane Epping, Essex CM16 5DQ / GB
Application number, filing date	99965162.3	06.12.1999
	[2001/40]
	WO1999US29042
Priority number, date	US19980111291P	07.12.1998 Original published format: US 111291 P
	[2001/40]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO0034451
	Date:	15.06.2000
	Language:	EN
	[2000/24]
	Type:	A1 Application with search report
	No.:	EP1137762
	Date:	04.10.2001
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 15.06.2000 takes the place of the publication of the European patent application.
	[2001/40]
	Type:	B1 Patent specification
	No.:	EP1137762
	Date:	08.10.2008
	Language:	EN
	[2008/41]
Search report(s)	International search report - published on:	US	15.06.2000
	(Supplementary) European search report - dispatched on:	EP	26.11.2004
Classification	IPC:	C12N9/24, A01N37/18, A61K38/43, A61P3/00	[2005/02]
	CPC:	A61K38/47 (EP,US); A61K38/43 (KR); A01K67/0275 (EP,US); A01K67/0276 (EP,US); A01K67/0278 (EP,US); A61K9/0019 (US); (+) A61P11/00 (EP); A61P21/00 (EP); A61P3/00 (EP); A61P3/08 (EP); A61P43/00 (EP); A61P9/04 (EP); C12N15/8509 (EP,US); C12N9/2408 (EP,US); C12Y302/0102 (EP,US); A01K2207/15 (EP,US); A01K2217/00 (EP,US); A01K2217/05 (EP,US); A01K2217/075 (EP,US); A01K2227/105 (EP,US); A01K2227/107 (EP,US); A01K2267/01 (EP,US); A01K2267/0306 (EP,US) (-)
	Former IPC [2001/40]	C12N9/24, A01N37/18, A61K38/43
Designated contracting states	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE [2001/40]
Extension states	AL	Not yet paid
	LT	Not yet paid
	LV	Not yet paid
	MK	Not yet paid
	RO	Not yet paid
	SI	Not yet paid
Title	German:	BEHANDLUNG DER POMPESCHEN KRANKHEIT	[2001/40]
	English:	TREATMENT OF POMPE'S DISEASE	[2001/40]
	French:	TRAITEMENT DE LA MALADIE DE POMPE	[2001/40]
Entry into regional phase	29.06.2001	National basic fee paid
	29.06.2001	Search fee paid
	29.06.2001	Designation fee(s) paid
	29.06.2001	Examination fee paid
Examination procedure	06.07.2000	Request for preliminary examination filed International Preliminary Examining Authority: US
	29.06.2001	Examination requested [2001/40]
	15.08.2001	Amendment by applicant (claims and/or description)
	31.03.2005	Despatch of a communication from the examining division (Time limit: M06)
	06.10.2005	Reply to a communication from the examining division
	26.10.2005	Despatch of a communication from the examining division (Time limit: M06)
	05.05.2006	Reply to a communication from the examining division
	05.10.2006	Despatch of a communication from the examining division (Time limit: M04)
	13.02.2007	Reply to a communication from the examining division
	01.03.2007	Despatch of a communication from the examining division (Time limit: M06)
	11.09.2007	Reply to a communication from the examining division
	01.10.2007	Despatch of a communication from the examining division (Time limit: M06)
	11.04.2008	Reply to a communication from the examining division
	24.04.2008	Communication of intention to grant the patent
	22.08.2008	Fee for grant paid
	22.08.2008	Fee for publishing/printing paid
Divisional application(s)	EP08164825.5 / EP2020438
Opposition(s)	Opponent(s)	01 07.07.2009 15.07.2009 ADMISSIBLE ZyStor Therapeutics, Inc. 10437 Innovation Drive, Suite 100 Milwaukee, WI 53226-4838 / US Opponent's representative Lock, Graham James, et al, et al Fry Heath & Spence LLP Unit A, Faraday Court Faraday Road Crawley, West Sussex RH10 9PU / GB
		02 07.07.2009 ADMISSIBLE Lingner, Margrit Michael-Huber-Weg 26 81667 München / DE Opponent's representative Sharples, Andrew John EIP Fairfax House 15 Fulwood Place London WC1V 6HU / GB
		[N/P]
	Former [2011/42]
	Opponent(s)	01 07.07.2009 15.07.2009 ADMISSIBLE ZyStor Therapeutics, Inc. 10437 Innovation Drive, Suite 100 Milwaukee, WI 53226-4838 / US Opponent's representative Lock, Graham James, et al, et al Fry Heath & Spence LLP The Gables Massetts Road Horley Surrey RH6 7DQ / GB
		02 07.07.2009 ADMISSIBLE Lingner, Margrit Michael-Huber-Weg 26 81667 München / DE Opponent's representative Sharples, Andrew John EIP Fairfax House 15 Fulwood Place London WC1V 6HU / GB
	Former [2011/07]
	Opponent(s)	01 07.07.2009 15.07.2009 ADMISSIBLE ZyStor Therapeutics, Inc. 10437 Innovation Drive, Suite 100 Milwaukee, WI 53226-4838 / US Opponent's representative Lock, Graham James, et al, et al Fry Heath & Spence LLP The Gables Massetts Road Horley Surrey RH6 7DQ / GB
		02 07.07.2009 Lingner, Margrit Michael-Huber-Weg 26 81667 München / DE Opponent's representative Zeman, Steven Michael, et al, et al Grünecker, Kinkeldey, Stockmair & Schwanhäusser Anwaltssozietät Leopoldstraße 4 DE-80802 München / DE
	Former [2009/34]
	Opponent(s)	01 07.07.2009 15.07.2009 ADMISSIBLE ZyStor Therapeutics, Inc. 10437 Innovation Drive, Suite 100 Milwaukee, WI 53226-4838 / US Opponent's representative Lock, Graham James, et al, et al Fry Heath & Spence LLP The Gables Massetts Road Horley Surrey RH6 7DQ / GB
		02 07.07.2009 Lingner, Margrit Michael-Huber-Weg 26 81667 München / DE Opponent's representative Dehmel, Albrecht, et al, et al Dehmel & Bettenhausen Patentanwälte Herzogspitalstrasse 11 80331 München / DE
	Former [2009/33]
	Opponent(s)	01 07.07.2009 ADMISSIBLE ZyStor Therapeutics, Inc. 10437 Innovation Drive, Suite 100 Milwaukee, WI 53226-4838 / US Opponent's representative Lock, Graham James Fry Heath & Spence LLP The Gables Massetts Road Horley Surrey RH6 7DQ / GB
	19.08.2009	Invitation to proprietor to file observations on the notice of opposition
	29.05.2010	Reply of patent proprietor to notice(s) of opposition
	24.03.2011	Date of oral proceedings
	10.05.2011	Despatch of interlocutory decision in opposition
	10.05.2011	Despatch of minutes of oral proceedings
	20.10.2015	Legal effect of revocation of patent [ N /P ]
	20.10.2015	Legal effect of revocation of patent [2016/23]
	06.05.2016	Despatch of communication that the patent will be revoked
Appeal following opposition	19.07.2011	Appeal received No. T1673/11
	14.09.2011	Statement of grounds filed
	20.10.2015	Result of appeal procedure: revocation of the patent
Fees paid	Renewal fee
	31.12.2001	Renewal fee patent year 03
	23.12.2002	Renewal fee patent year 04
	29.12.2003	Renewal fee patent year 05
	23.12.2004	Renewal fee patent year 06
	27.12.2005	Renewal fee patent year 07
	27.12.2006	Renewal fee patent year 08
	24.12.2007	Renewal fee patent year 09
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition Tooltip	CH	08.10.2008
	CY	08.10.2008
	LI	08.10.2008
	MC	31.12.2008
	[2016/34]
Former [2010/44]	CY	08.10.2008
	MC	31.12.2008
Former [2010/06]	MC	31.12.2008
Documents cited:	Search	[X]WO9705771 (PHARMING BV [NL], et al) [X] 1-19 * page 2, line 13 - line 29; claims 1,4,5 * * page 4, line 14 - page 5, line 4 * * page 19, line 12 - line 37 *;
		[X] - KIKUCHI T ET AL, "Clinical and metabolic correction of pompe disease by enzyme therapy in acid maltase-deficient quail.", THE JOURNAL OF CLINICAL INVESTIGATION. 15 FEB 1998, (19980215), vol. 101, no. 4, ISSN 0021-9738, pages 827 - 833, XP002922373 [X] 1-19 * the whole document * DOI: http://dx.doi.org/10.1172/JCI1722
		[X] - YANG H W ET AL, "Recombinant human acid alpha-glucosidase corrects acid alpha-glucosidase-deficient human fibroblasts, quail fibroblasts, and quail myoblasts.", PEDIATRIC RESEARCH. MAR 1998, (199803), vol. 43, no. 3, ISSN 0031-3998, pages 374 - 380, XP001041668 [X] 1-13 * the whole document *
		[X] - YANG H W ET AL, "Recombinant human acid alpha-glucosidase corrects acid glucosidase deficient human fibroblasts, quail fibroblasts and quail myoblasts", AMERICAN JOURNAL OF HUMAN GENETICS, & 46TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF HUMAN GENETICS; SAN FRANCISCO, CALIFORNIA, USA; OCTOBER 29-NOVEMBER 2, 1996, (1996), vol. 59, no. 4 SUPPL., ISSN 0002-9297, page A209, XP000934192 [X] 1-13 * the whole document *
		[X] - BYRNE BARRY J ET AL, "Reconstitution of acid alpha-glucosidase activity in a mouse model of cardioskeletal myopathy, Pompe's disease", CIRCULATION, & 71ST SCIENTIFIC SESSIONS OF THE AMERICAN HEART ASSOCIATION; DALLAS, TEXAS, USA; NOVEMBER 8-11, 1998, (19981027), vol. 98, no. 17 SUPPL., ISSN 0009-7322, page I737, XP001041662 [X] 1-13 * the whole document *
	International search	[X] - DE BARSY ET AL., "Enzyme Replacement in Pompe Disease: an Attempt with Purified Human Acid Alpha Glucosidase", BIRTH DEFECTS ORIGINAL ARTICLE SERIES, (197303), vol. 9, no. 2, pages 184 - 190, XP002922372
		[Y] - KIKUCHI ET AL., "Clinical and Metabolic Correction of Pompe Disease by Enzyme Therapy in Acid Maltase-Deficient Quail", J. CLIN. INVEST., (199802), vol. 101, no. 4, pages 827 - 833, XP002922373 DOI: http://dx.doi.org/10.1172/JCI1722
		[Y] - VAN HOVE ET AL., "Purification of Recombinant Human Precursor Acid Alpha Glucosidase", BIOCHEMISTRY AND MOLECULAR BIOLOGY INTERNATIONAL, (199710), vol. 43, no. 3, pages 613 - 623, XP002108774
	by applicant	WO9108216
		WO9203917
		- HIRSCHHORN ET AL., The Metabolic and Molecular Bases of Inherited Disease, MCGRAW-HILL, (1995), pages 2443 - 2464
		- HERS, BIOCHEM. J., (1963), vol. 86, pages 11 - 16
		- SCOTT ET AL., AM. J. HUM. GENET, (1990), vol. 47, pages 802 - 807
		- WILSON ET AL., PNAS, (1990), vol. 87, pages 8531 - 8535
		- STEIN ET AL., J. BIOL. CHEM., page 264
		- RICHARDS ET AL., J. BIOL. CHEM., (1981), vol. 256, pages 526 - 532
		- CAMPBELL ET AL., NUCLEIC ACIDS RES., (1984), vol. 12, pages 8685 - 8697
		- JONES ET AL., J. BIOL. CHEM., (1985), vol. 260, pages 7042 - 7050
		- YU-LEE; ROSEN, J. BIOL. CHEM., (1983), vol. 258, pages 10794 - 10804
		- HALL, BIOCHEM. J., (1987), vol. 242, pages 735 - 742
		- GORODETSKY ET AL., GENE, (1988), vol. 66, pages 87 - 96
		- ALEXANDER ET AL., EUR. J. BIOCHEM., (1988), vol. 178, pages 395 - 401
		- BRIGNON ET AL., FEBS LETT, (1977), vol. 188, pages 48 - 55
		- JAMIESON ET AL., GENE, page 61
		- BRADLEY ET AL., NATURE, (1984), vol. 309, pages 255 - 258
		- JAENISCH, SCIENCE, (1988), vol. 240, pages 1468 - 1474
		- HOEFSLOOT ET AL., BIOCHEM. J., (1990), vol. 272, pages 493 - 497
		GB19640098074

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.1.24; 35p